当前位置: X-MOL 学术Drug Resist. Updat. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Tumor-associated macrophage (TAM)-secreted CCL22 confers cisplatin resistance of esophageal squamous cell carcinoma (ESCC) cells via regulating the activity of diacylglycerol kinase α (DGKα)/NOX4 axis
Drug Resistance Updates ( IF 15.8 ) Pub Date : 2024-01-18 , DOI: 10.1016/j.drup.2024.101055
Jie Chen 1 , Di Zhao 2 , Lingyuan Zhang 3 , Jing Zhang 3 , Yuanfan Xiao 3 , Qingnan Wu 2 , Yan Wang 2 , Qimin Zhan 4
Affiliation  

Tumor-associated macrophages (TAMs) are often associated with chemoresistance and resultant poor clinical outcome in solid tumors. Here, we demonstrated that TAMs-released chemokine-C-C motif chemokine 22 (CCL22) in esophageal squamous cell carcinoma (ESCC) stroma was tightly correlated with the chemoresistance of ESCC patients. TAMs-secreted CCL22 was able to block the growth inhibitory and apoptosis-promoting effects of cisplatin on ESCC cells. Mechanistically, CCL22 stimulated intratumoral diacylglycerol kinase α (DGKα) to produce phosphatidic acid (PA), which suppressed the activity of NADPH oxidase 4 (NOX4) and then blocked the overproduction of intratumoral reactive species oxygen (ROS) induced by cisplatin. CCL22 activated DGKα/nuclear factor-κB (NF-κB) axis to upregulate the level of several members of ATP binding cassette (ABC) transporter superfamily, including ABC sub-family G member 4 (ABCG4), ABC sub-family A member 3 (ABCA3), and ABC sub-family A member 5 (ABCA5), to lower the intratumoral concentration of cisplatin. Consequently, these processes induced the cisplatin resistance in ESCC cells. In xenografted models, targeting DGKα with 5’-cholesterol-conjugated small-interfering (si) RNA enhanced the chemosensitivity of cisplatin in ESCC treatment, especially in the context of TAMs. Our data establish the correlation between the TAMs-induced intratumoral metabolic product/ROS axis and chemotherapy efficacy in ESCC treatment and reveal relevant molecular mechanisms.

中文翻译:


肿瘤相关巨噬细胞(TAM)分泌的CCL22通过调节二酰甘油激酶α(DGKα)/NOX4轴的活性赋予食管鳞状细胞癌(ESCC)细胞顺铂耐药性



肿瘤相关巨噬细胞(TAM)通常与实体瘤的化疗耐药性和由此导致的不良临床结果相关。在这里,我们证明食管鳞状细胞癌(ESCC)基质中 TAM 释放的趋化因子-CC 基序趋化因子 22(CCL22)与 ESCC 患者的化疗耐药性密切相关。 TAM 分泌的 CCL22 能够阻断顺铂对 ESCC 细胞的生长抑制和凋亡促进作用。从机制上讲,CCL22刺激瘤内二酰甘油激酶α(DGKα)产生磷脂酸(PA),磷脂酸(PA)抑制NADPH氧化酶4(NOX4)的活性,然后阻止顺铂诱导的瘤内活性氧(ROS)的过量产生。 CCL22激活DGKα/核因子-κB(NF-κB)轴,上调ATP结合盒(ABC)转运蛋白超家族多个成员的水平,包括ABC亚家族G成员4(ABCG4)、ABC亚家族A成员3 (ABCA3) 和 ABC 亚家族 A 成员 5 (ABCA5),以降低顺铂的瘤内浓度。因此,这些过程诱导了 ESCC 细胞的顺铂耐药性。在异种移植模型中,用 5'-胆固醇缀合的小干扰 (si) RNA 靶向 DGKα 可增强 ESCC 治疗中顺铂的化疗敏感性,特别是在 TAM 的情况下。我们的数据建立了 TAM 诱导的瘤内代谢产物/ROS 轴与 ESCC 治疗中化疗疗效之间的相关性,并揭示了相关的分子机制。
更新日期:2024-01-18
down
wechat
bug